Immune checkpoint inhibitors: here to stay
- PMID: 37969375
- PMCID: PMC10643939
- DOI: 10.21037/tcr-23-1343
Immune checkpoint inhibitors: here to stay
Keywords: Endometrial cancer (EC); checkpoint inhibitors; microsatellite instability (MSI); mismatch repair deficient (MMR deficient).
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1343/coif). FMC reports receiving payments for lectures from GSK and MSD. The other authors have no conflicts of interest to declare.
Comment on
-
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources